

(43) International Publication Date
18 September 2014 (18.09.2014)

(51) International Patent Classification:

A61K 48/00 (2006.01)

(21) International Application Number:

PCT/US2014/028855

(22) International Filing Date:

14 March 2014 (14.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/786,946 15 March 2013 (15.03.2013) US

(71) Applicant: **TECHULON INC.** [US/US]; 2200 Kraft Drive, Suite 2475, Blacksburg, VA 24060 (US).(72) Inventors: **MALONE, Brett**; 567 Riverbend Dr., Pearisburg, VA 24134 (US). **BRYSON, Joshua**; 1218 Brook Circle, Blacksburg, VA 24060 (US).(74) Agents: **ESMOND, Robert, W.** et al.; Sterne, Kessler, Goldstein & Fox, P.L.L.C., 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))


(54) Title: ANTISENSE MOLECULES FOR TREATMENT OF *STAPHYLOCOCCUS AUREUS* INFECTION5 μ M PNA treatments in Methicillin Resistant *Staph. Aureus*

FIGURE 1

(57) Abstract: Disclosed are antisense molecules and compositions for the treatment of *Staphylococcus aureus* infection. The antisense molecules and compositions comprise nucleic acid molecules, such as RNA, DNA, or nucleic acid molecules with modified backbones, such as PNA. The antisense molecules and compositions inhibit expression of membrane stability proteins in *Staphylococcus aureus*; are optionally conjugated to cell penetration molecules such as peptides; and are optionally administered in the form of a nanoparticle composition.